A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia
Top Cited Papers
Open Access
- 15 November 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (5), 1155-1163
- https://doi.org/10.1086/317451
Abstract
In this double-blind study to compare safety of 2 lipid formulations of amphotericin B, neutropenic patients with unresolved fever after 3 days of anKeywords
This publication has 29 references indexed in Scilit:
- Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven AspergillosisClinical Infectious Diseases, 1999
- Invasive AspergillosisClinical Infectious Diseases, 1998
- 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained FeverClinical Infectious Diseases, 1997
- Lipid Formulations of Amphotericin B: Recent Progress and Future DirectionsClinical Infectious Diseases, 1996
- Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levelsMycoses, 1995
- Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related ToxicitiesJournal of Liposome Research, 1993
- Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin BJournal of Liposome Research, 1993
- Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male VolunteersThe Journal of Infectious Diseases, 1991
- Amphotericin B: 30 Years of Clinical ExperienceClinical Infectious Diseases, 1990
- Empiric antifungal therapy in febrile granulocytopenic patientsAmerican Journal Of Medicine, 1989